NCT02583542 - A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions

Triple-Negative Breast CancerSquamous Cell Lung CancerNon-squamous Cell Lung Cancer With KRAS MutationsNon-squamous Cell Lung Cancer With Wild-type KRAS

Interventions

DRUG

AZD2014

AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.

DRUG

AZD6244

Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.

Trial Locations (4)

B15 2TT

University Hospitals Birmingham NHS Foundation Trust, Birmingham

EC1M 6BQ

Barts Health NHS Trust, London

W1T 7HA

University College London Hospitals NHS Foundation Trust, London

M20 4BX

Christie NHS Foundation Trust, Manchester